دورية أكاديمية
Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes : a minireview
| العنوان: | Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes : a minireview |
|---|---|
| المؤلفون: | Wieczorek-Surdacka, Ewa, Surdacki, Andrzej, Świerszcz, Jolanta, Chyrchel, Bernadeta |
| سنة النشر: | 2020 |
| المجموعة: | Jagiellonian University Repository |
| مصطلحات موضوعية: | sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, renoprotection, diabetic kidney disease, type 2 diabetes, cardiovascular outcome trials, clinical practice guidelines |
| الوصف: | Intensive hypoglycemic treatment is the strongest preventive strategy against the development of microvascular complications of type 2 diabetes (T2DM), including diabetic nephropathy. However, some antidiabetic drugs, i.e. sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have an additional renoprotective effect beyond glucose control by itself. Similar, both SGLT-2i and GLP1-RA have been demonstrated to decrease the risk of adverse cardiovascular (CV) events in CV outcome trials. Nevertheless, there are relevant differences in CV and renal effects of SGLT-2i and GLP1-RA. First, SGLT2i reduced the incidence and progression of albuminuria and prevented loss of kidney function, while predominant renal benefits of GLP1-RA were driven by albuminuria outcomes. Second, the risk of heart failure (HF) hospitalizations decreased on SGLT2i but not on GLP1-RA, which gives priority to SGLT2i in T2DM and HF, especially with depressed EF. Third, either GLP1-RA (reducing predominantly atherosclerosis-dependent events) or SGLT-2i, should be used in T2DM and established atherosclerotic CV disease (ASCVD) or other indicators of high CV risk. In this review, we have briefly compared clinical practice guidelines of the American Diabetes Association (2020 and 2021 versions), Polish Diabetes Association (2020) and the European Society of Cardiology/European Association for the Study of Diabetes (2019), with a focus on the choice between SGLT-2i and GLP1-RA in patients with diabetic kidney disease. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0015-5616 |
| العلاقة: | Folia Medica Cracoviensia, T. 60, nr 4, s. 97-101; https://ruj.uj.edu.pl/xmlui/handle/item/270312Test |
| DOI: | 10.24425/fmc.2020.136207 |
| الإتاحة: | https://doi.org/10.24425/fmc.2020.136207Test https://ruj.uj.edu.pl/xmlui/handle/item/270312Test |
| حقوق: | Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 3.0 Polska |
| رقم الانضمام: | edsbas.61F9580 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 00155616 |
|---|---|
| DOI: | 10.24425/fmc.2020.136207 |